Adherence and persistence to rivaroxaban in non-valvular atrial fibrillation patients receiving 30- or 90-day supply prescription fills.
Craig I ColemanThomas J BunzVeronica AshtonPublished in: Current medical research and opinion (2021)
Dispensing 90-day supply fills with rivaroxaban appears to increase the proportion of patients achieving acceptable (PDC ≥80%) adherence as well as mean adherence compared to 30-day supply fills. Ninety-day rivaroxaban fills may also result in improved persistence vs. 30-day fills.
Keyphrases
- atrial fibrillation
- oral anticoagulants
- venous thromboembolism
- end stage renal disease
- catheter ablation
- left atrial
- left atrial appendage
- direct oral anticoagulants
- pulmonary embolism
- heart failure
- chronic kidney disease
- ejection fraction
- percutaneous coronary intervention
- peritoneal dialysis
- type diabetes
- metabolic syndrome
- adipose tissue
- coronary artery disease
- weight loss